Related Experiment Video
Updated: Aug 2, 2025
Author Spotlight: Advancing Liver Regeneration Research through ALPPS Mouse Model
Published on: January 19, 2024
Future liver remnant augmentation preceding ex vivo hepatectomy with IVC replacement: a strategy to achieve R0
Maria Baimas-George1,2, Matthew S Strand1, Joshua M Davis1
1Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, Atrium Health, Charlotte, NC, 28203, USA.
Purpose:
Ex vivo hepatectomy with autotransplantation (EHAT) provides opportunity for R0 resection. As EHAT outcomes after future liver remnant (FLR) augmentation techniques are not well documented, we examine results of EHAT after augmentation for malignant tumors.
Methods:
Retrospective analysis of six cases of EHAT was performed. Of these, four occurred after preoperative FLR augmentation between 2018 and 2022.
Results:
Six patients were offered EHAT of 26 potential candidates. Indications for resection were involvement of hepatic vein outflow and inferior vena cava (IVC) with metastatic colorectal carcinoma (n = 3), cholangiocarcinoma (n = 2), or leiomyosarcoma (n = 1). Five patients were treated with neoadjuvant chemotherapy and four had preoperative liver augmentation. One hundred percent of cases achieved R0 resection. Of the augmented cases, three patients are alive after median follow-up of 28 months. Postoperative mortality due to liver failure was 25% (n = 1).
Conclusions:
For select patients with locally advanced tumors involving all hepatic veins and the IVC for whom conventional resection is not an option, EHAT provides opportunity for R0 resection. In addition, in patients with inadequate FLR volume, further operative candidacy with acceptable results can be achieved by combined liver augmentation techniques. To better characterize outcomes in this small subset, a registry is needed.
